biology

Vusolimogene oderparepvec

Vusolimogene oderparepvec is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Vusolimogene oderparepvec rather than just read about it. In short: Vusolimogene oderparepvec, sold under the brand name Tudriqev, is an anti-cancer medication used for the treatment of melanoma. It is a genetically modified herpes simplex virus type 1 oncolytic virus that is injected directly into tumors.

Key takeaways

Vusolimogene oderparepvec belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Vusolimogene oderparepvec to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Vusolimogene oderparepvec from memory before moving on to harder problems.

Reference excerpt

Vusolimogene oderparepvec, sold under the brand name Tudriqev, is an anti-cancer medication used for the treatment of melanoma. It is a genetically modified herpes simplex virus type 1 oncolytic virus that is injected directly into tumors. The most common non-laboratory adverse reactions include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Vusolimogene oderparepvec was approved for medical use in the United States in August 2026.

Medical uses Vusolimogene oderparepvec is indicated in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1-blocking antibody-based regimen. Vusolimogene oderparepvec is an oncolytic viral therapy based on a modified herpes simplex virus type 1 that is engineered to selectively target and destroy cancer cells. Once inside a tumor, the virus replicates and breaks cancer cells apart, while simultaneously triggering the body’s immune system to recognize and attack the cancer. When used in combination with nivolumab, an anti-PD-1 immunotherapy, vusolimogene oderparepvec may help restore an anti-tumor immune response in patients whose cancer had previously stopped responding to immunotherapy.

Adverse effects The US prescribing information includes warnings and precautions for accidental exposure, herpetic infection or reactivation, injection procedure complications, and immune-mediated events. The most common non-laboratory adverse reactions include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain.

Composition Vusolimogene oderparepvec is an oncolytic herpes virus that was created by genetically engineering a strain of herpes simplex virus 1 (HSV-1) to express GM-CSF and a glycoprotein from the envelope of gibbon ape leukemia virus.

History The safety and efficacy of vusolimogene oderparepvec were evaluated in IGNYTE (NCT03767348), an open-label, multiregional, single-arm trial in 140 adults with stage IIIB, IIIC or IV unresectable advanced melanoma who experienced disease progression on at least eight consecutive weeks of prior anti-programmed death receptor-1-based therapy. Of the 140 participants, 91 participants with at least one noninjected lesion were included in the efficacy-evaluable population.

Society and culture

Legal status Vusolimogene oderparepvec was approved for medical use in the United States in August 2026. The US Food and Drug Administration (FDA) granted the application for vusolimogene oderparepvec, in combination with nivolumab, breakthrough therapy designation. The FDA granted the approval of Tudriqev to Replimune.

Names Vusolimogene oderparepvec is the international nonproprietary name and the United States Adopted Name. Vusolimogene oderparepvec is sold under the brand name Tudriqev.

References

External links "Vusolimogene Oderparepvec ( Code - C158074 )". EVS Explore. Clinical trial number NCT03767348 for "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (IGNYTE)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Vusolimogene oderparepvec

Start with the simplest possible case. Write down what Vusolimogene oderparepvec claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Vusolimogene oderparepvec before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Vusolimogene oderparepvec ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Vusolimogene oderparepvec

In research: Vusolimogene oderparepvec appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Vusolimogene oderparepvec in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Vusolimogene oderparepvec is common in secondary-school and first-year university syllabi. It links to neighbouring topics Approved gene therapies, Cancer treatments, Drugs not assigned an ATC code, so understanding it makes those chapters shorter.
In everyday life: Look for Vusolimogene oderparepvec outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Vusolimogene oderparepvec” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Vusolimogene oderparepvec in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Vusolimogene oderparepvec means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Vusolimogene oderparepvec out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Vusolimogene oderparepvec in simple terms?

Why does Vusolimogene oderparepvec matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Vusolimogene oderparepvec?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Vusolimogene oderparepvec.